IPH5201
Based on 1 Customer Validation
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.24%
- 分子量:145.12 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Human
ENTPD1/CD39
IPH5201 enhances phenotypic maturation and activation of dendritic cells and macrophages, and restores ATP-suppressed T-cell proliferation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
性状 Liquid
-
分子量 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
I[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)